Alzheimer; News from the web:
Read all about it HERE
Category Archives: Research
The Brain plays defense
Alzheimer; News from the web:
Buildups of “clumpy” proteins in the brain are well-known hallmarks of Alzheimer’s, but not everyone who has them goes on to develop this neurodegenerative disease. Why is that? New research investigates.
Read all about it HERE
Dolphins and Alzheimer’s
Alzheimer; News from the web:
Poor responses to insulin have been closely associated with Alzheimer’s disease in humans, and previous research has shown that bottlenose dolphins can also develop insulin resistance. That, combined with the recent discovery of amyloid plaques and tangled clumps of fibers in bottlenose dolphin brains, led the researchers to believe that dolphins, like us, may develop signs of Alzheimer’s disease as a result of high levels of blood sugar and insulin.
Read all about it HERE
Vaccination against Alzheimer’s coming?
Alzheimer; News from the web:
Research from the Universities of Dundee and Oxford has shown how combining the tetanus vaccine with a viral particle that normally affects cucumbers can be used to treat psoriasis and allergies, and may even protect against Alzheimer’s disease.
Read all about it HERE
Israeli researchers may have found a trigger!
Alzheimer; News from the web:
Dr. Debbie Toiber, of the BGU Department of Life Sciences, and her team discovered that a specific protein — Sirtuin-6 (SIRT6) — is severely reduced in the brains of Alzheimer’s patients. SIRT6 is critical to the repair of DNA, the deterioration of which “is the beginning of the chain that ends in neurodegenerative diseases in seniors,” she explains.
The blood-brain barrier prevents us from simply being able to inject the protein into the brain to replenish its supply. Dr. Toiber is currently working on finding a way to increase the expression of the protein into the brain.
Read all about it HERE
Four trials go to human phase!
Alzheimer; News from the web:
Ionis and Biogen are bringing to bear the Ionis drug technology called antisense, which targets diseases processes at the genetic level. It blocks or modifies production of proteins involved in disease.
The Phase 1/2a study of the Alzheimer’s drug, IONIS-MAPTRx, seeks evidence of safety and signs of activity. It’s to be given in 44 patients with mild Alzheimer’s over three months.The drug targets microtubule-associated tau protein, also called MATP, or tau, an abnormal protein associated with Alzheimer’s.
Read all about it HERE